A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to...
show moreAuthor | cancerGRACE |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Browse Spreaker Catalogue to discover great new content
Browse Spreaker Catalogue to discover great new content
It's so quiet here...
Time to discover new episodes!